CRISPR GENOMIC CURE MARKET ANALYSIS

Market News

Recent Developments

New product launches

• On June 8, 2023, Parse Biosciences, a leading provider of accessible and scalable single-cell sequencing solutions, announced the launch of CRISPR Detect, enabling single-cell pooled CRISPR screens at unprecedented scale.
• In January 2021, QIAGEN, a provider of molecular testing solutions, announced the launch of the QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions, which allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.
• In June 2020, Merck KGaA, a leading science and technology company, and 10x Genomics, Inc., a single-cell and spatial genomics technology company, announced that they had developed a powerful new option for biological experiments.

Collaboration and agreements

• On October 3, 2023, Regeneron Pharmaceuticals, Inc., a biotechnology company, and Intellia Therapeutics, Inc., a biotechnology company, announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.
• In October 2021, Merck KGaA announced that its Life Science business sector had signed an agreement licensing its patented CRISPR-Cas9 technology to Cellecta, Inc., a functional genomics products and services provider based in Mountain View, California, U.S.
• In January 2020, ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP), announced it had signed an agreement with New England Biolabs (NEB), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.